NUVAMA.NS(NUVAMA.NS)
NUVAMA.NS
No analyst ratings available
No analyst price targets available for NUVAMA.NS
Analyst coverage may not be available for this symbol
No recent analyst actions
| Metric | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|
| Revenue Avg | $36.35B | $42.27B | $49.56B | $54.02B |
| Low | $35.38B | $40.96B | $49.14B | $52.45B |
| High | $38.18B | $45.50B | $49.98B | $57.49B |
| EBITDA Avg | $28.78B | $33.46B | $39.23B | $42.76B |
| Low | $28.01B | $32.43B | $38.90B | $41.52B |
| High | $30.23B | $36.02B | $39.57B | $45.52B |
| EBIT Avg | $27.46B | $31.93B | $37.44B | $40.81B |
| Low | $26.73B | $30.95B | $37.12B | $39.62B |
| High | $28.85B | $34.37B | $37.76B | $43.43B |
| Net Income Avg | $12.24B | $14.42B | $17.15B | $18.75B |
| Low | $11.81B | $13.89B | $15.93B | $18.05B |
| High | $12.85B | $15.46B | $18.34B | $20.32B |
| EPS Avg | $67.31 | $79.90 | $94.46 | $103.04 |
| Low | $64.92 | $76.32 | $87.56 | $99.16 |
| High | $70.63 | $84.94 | $100.80 | $111.67 |
| Analysts (Rev / EPS) | 7 / 7 | 7 / 7 | 4 / 4 | 3 / 2 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 |
|---|---|---|---|
| Revenue Avg | $8.80B | $9.34B | $9.80B |
| Low | $8.74B | $9.28B | $9.74B |
| High | $8.86B | $9.40B | $9.87B |
| EBITDA Avg | $6.97B | $7.39B | $7.76B |
| Low | $6.92B | $7.34B | $7.71B |
| High | $7.01B | $7.44B | $7.81B |
| EBIT Avg | $6.65B | $7.06B | $7.41B |
| Low | $6.60B | $7.01B | $7.36B |
| High | $6.69B | $7.10B | $7.46B |
| Net Income Avg | — | — | — |
| Low | — | — | — |
| High | — | — | — |
| EPS Avg | — | — | — |
| Low | — | — | — |
| High | — | — | — |
| Analysts (Rev / EPS) | 2 / — | 1 / — | 1 / — |